Technical Analysis for CNTA - Centessa Pharmaceuticals plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.55% | |
Pocket Pivot | Bullish Swing Setup | -2.55% | |
Outside Day | Range Expansion | -2.55% | |
Fell Below 20 DMA | Bearish | -2.00% | |
NR7 | Range Contraction | -2.00% | |
NR7-2 | Range Contraction | -2.00% | |
Narrow Range Bar | Range Contraction | -2.00% | |
MACD Bearish Signal Line Cross | Bearish | -2.11% |
Alert | Time |
---|---|
20 DMA Resistance | about 8 hours ago |
Outside Day | about 9 hours ago |
Non-ADX 1,2,3,4 Bearish Retracement Entry | about 9 hours ago |
Fell Below Previous Day's Low | about 9 hours ago |
Down 3% | about 9 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Centessa Pharmaceuticals plc Description
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Pharmaceutical Solid Tumors Drugs Immunotherapy Non Small Cell Lung Cancer Lung Cancer Orphan Drug Epidermal Growth Factor Receptor Idiopathic Pulmonary Fibrosis Pulmonary Arterial Hypertension Oncogenes Lupus Hematological Malignancies Narcolepsy Non Small Cell Lung Carcinoma Alpha 1 Antitrypsin Deficiency Hemophilia A Treatment Of Hemophilia Autosomal Dominant Polycystic Kidney Disease Cutaneous Squamous Cell Carcinoma Systemic Sclerosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.45 |
52 Week Low | 5.15 |
Average Volume | 245,240 |
200-Day Moving Average | 8.42 |
50-Day Moving Average | 9.05 |
20-Day Moving Average | 9.06 |
10-Day Moving Average | 8.96 |
Average True Range | 0.51 |
RSI (14) | 45.95 |
ADX | 13.03 |
+DI | 20.50 |
-DI | 21.07 |
Chandelier Exit (Long, 3 ATRs) | 8.71 |
Chandelier Exit (Short, 3 ATRs) | 9.43 |
Upper Bollinger Bands | 9.96 |
Lower Bollinger Band | 8.16 |
Percent B (%b) | 0.35 |
BandWidth | 19.84 |
MACD Line | -0.04 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0176 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.48 | ||||
Resistance 3 (R3) | 9.49 | 9.27 | 9.37 | ||
Resistance 2 (R2) | 9.27 | 9.10 | 9.27 | 9.33 | |
Resistance 1 (R1) | 9.04 | 8.99 | 8.93 | 9.03 | 9.29 |
Pivot Point | 8.82 | 8.82 | 8.76 | 8.81 | 8.82 |
Support 1 (S1) | 8.58 | 8.64 | 8.47 | 8.57 | 8.31 |
Support 2 (S2) | 8.36 | 8.54 | 8.36 | 8.27 | |
Support 3 (S3) | 8.13 | 8.36 | 8.23 | ||
Support 4 (S4) | 8.12 |